Entrada Q2 2026: $223M Cash, Runway to Q3 2027, and a Pipeline of Clinical Catalysts
TRDA sits 47% above its 52-week low of $4.93.
Summary
Entrada's Q2 2026 filing reveals a $223 million cash position funding operations into Q3 2027, a widening net loss, and a clear timeline of clinical catalysts that will define the company's trajectory over the next 12 months.
Key Events · Earnings and Guidance · TRDA
-
Cash Runway Extended into Q3 2027
Cash, cash equivalents and marketable securities totaled $223.0 million as of June 30, 2026, providing a runway into the third quarter of 2027 based on current operating plans.
-
Net Loss Widens on Lower Collaboration Revenue
Net loss for the first half of 2026 was $82.5 million, up from $60.5 million in the prior year period, driven by a $20.7 million decline in collaboration revenue as the Vertex VX-670 research plan nears completion.
-
Key Clinical Catalysts Stacked Through Early 2027
Upcoming data readouts include ELEVATE-45-201 Cohort 1 in October 2026, ELEVATE-44-201 open-label data by year-end 2026, and ELEVATE-44-201 Cohort 2 topline results in Q1 2027. Vertex is on track to report VX-670 Phase 1/2 data in H2 2026.
-
President and COO Adopts 10b5-1 Trading Plan
Nathan Dowden, President and COO, adopted a Rule 10b5-1 trading plan on June 3, 2026, covering the potential sale of up to 73,538 shares through June 5, 2027.
Analysis · TRDA · Life Sciences
Entrada's 10-Q offers the first look at its financial health and clinical momentum since the market's negative reaction to Cohort 1 data in May. With $223 million in cash and equivalents, the company is funded into the third quarter of 2027—a critical buffer as it advances multiple DMD programs and awaits Vertex's VX-670 data in the second half of 2026. The net loss widened to $82.5 million for the first half of 2026, driven by lower collaboration revenue and sustained R&D spending. The filing also details upcoming catalysts: ELEVATE-45-201 Cohort 1 data in October 2026, ELEVATE-44-201 open-label data by year-end, and Cohort 2 topline results in Q1 2027. These events will determine whether the early functional signals translate into a competitive profile. The adoption of a 10b5-1 plan by the President and COO is a routine disclosure but worth noting alongside the recent insider selling pattern.
At the time of this filing, TRDA was trading at $7.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $281.1M. The 52-week trading range was $4.93 to $16.45. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.